ANNA-BIOSCIENCES
22.6.2021 15:02:10 CEST | Business Wire | Press release
Anna Biosciences, a drug discovery company focused on novel therapies in immuno-oncology, virology, and neurodegenerative diseases, today announces its entry in the fight against COVID-19 with the introduction of its immunotherapy platform, Syntem.
The Anna Biosciences Syntem Platform deploys engineered proprietary molecules to create synthetic immunity. Syntem’s lab-made molecules are multi-specific: they first target and flag the pathology, and then elicit an immune reaction that targets the virus or disease.
Research indicates the Syntem Platform can inhibit viral infection and aid in the removal of COVID-19 infected cells. Showing promise as both a prophylactic and a treatment, there is considerable hope that in addition to supporting the broader population, immunocompromised patients will be able to safely use Syntem to prevent infection. Importantly, Syntem also exhibits high potential against COVID variants. In the case of COVID-19, and coronaviruses more generally, the Syntem Platform represents a significant new tool in the arsenal against these rapidly evolving diseases.
With today’s announcement, Anna Biosciences underscores both its initial successes in the lab and the successful patenting of the Syntem Platform. The company is now accelerating its commercialization effort to bring this potential COVID-19 treatment to market.
The Syntem Platform also shows strong promise for use against cancer and other pathogens. Research into the application of Syntem for oncological targets is currently underway. The resulting therapies could offer precision targeting, and the potential to mitigate side effects while being easier to administer to patients.
“Like vaccines in the 20th century, synthetic small molecule immunotherapy is on the precipice of advancing human health in untold ways. A powerful new tool is on the horizon in our fight against coronaviruses. And that’s just the beginning of this technology’s potential,” said Dr. Anthony Rullo, a scientific co-founder of Anna Biosciences and assistant professor of medicine at McMaster University in Ontario, Canada. “I’m extremely proud of our team, and the extraordinary effort of everyone involved at Anna Biosciences in the furthering of this technology.”
About Anna Biosciences
Anna Biosciences is a drug discovery company that uses decentralized partnerships to develop and advance new therapies for better patient outcomes. Anna Biosciences’ first initiative, the Syntem Platform, is developing proprietary molecules to trigger synthetic immunity for COVID-19 and beyond.
Anna Biosciences will continue to develop the Syntem Platform modality for additional therapies for a range of diseases. The company is currently working on the implementation of this approach to activate immune cells that can recognize and attack cancers.
For more information, visit http://annabiosciences.com/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210622005353/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon Team Awarded ARPA-H Contract to Transform Care During Labor and Childbirth24.6.2026 13:05:00 CEST | Press release
New wearable monitoring system will improve clinical assessment of fetal health Carnegie Mellon University is leading a multi-university team that has secured an award of up to $39.3 million from the Advanced Research Projects Agency for Health (ARPA-H) to develop a wearable monitoring system to better identify fetal distress and its cause, enabling a safer labor and delivery experience for mothers and babies. The system, called OMEGA, or Optical, Mechanical, and Electrical Global Assessment of fetal hypoxia, aims to replace 50-year old, indirect, unreliable fetal heart rate monitoring technology with a unified, real-time assessment of fetal oxygen delivery and adaptive capacity. The project is under ARPA-H’s Making Obstetric Care Smart program, which is led by ARPA-H Program Manager Kate Arnold, M.D., MBA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260624524685/en/ Carnegie Mellon University is leading a multi-universit
€243B Tech Spend Ahead, but Only 1 in 4 Firms Achieves Scale: WBAM Research Reveals Structural Paradox24.6.2026 12:28:00 CEST | Press release
Research report by Monitor Deloitte and Objectway investigates how and why as-a-service models are gaining ground, and what separates successful execution from failed implementation.Key takeaways Firms are layering resources onto legacy, widening the gap between investment intensity and operational scalability Technology investment alone is insufficient. The real differentiator lies in how Tech&Ops capabilities are sourced, orchestrated, and delivered As-a-service adoption is set to triple in the next 2–3 years, emerging as a key lever to unlock scale According to research conducted by Monitor Deloitte, a consultancy firm, and Objectway, a growth partner for the financial services industry, wealth, banking and asset management (WBAM) firms are investing at record levels, with Technology & Operations spending reaching €173 billion globally and set to hit €243 billion by 2029. However, yet only around one in four firms has achieved true front-to-back scalability, growing their business w
PUMA Dominates HYROX World Championships From Elite Athlete Performances to Community Initiatives24.6.2026 12:15:00 CEST | Press release
Global sports brand PUMA continued its HYROX dominance at the 2026 HYROX World Championships with a host of standout elite athlete performances and iconic community moments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260624897869/en/ Global sports brand PUMA continued its HYROX dominance at the 2026 HYROX World Championships with a host of standout elite athlete performances and iconic community moments, including Jake Williamson (left) and Hunter McIntyre in the Men’s Elite15 Doubles. Leading the charge was Jess Pettrow, who won the Mixed Relay with Australia for the second year in a row, with the team defending their title with an epic time of 50:19. Pettrow’s golden moment followed a fourth place finish with partner Joanna Wietrzyk in the Women’s Elite 15 Doubles, making it a highly successful weekend for the PUMA athlete. In addition to her strong showing in the Women’s Elite Doubles, Australian athlete Wietrzyk also
Rockstar Games Announces Pre-Orders for Grand Theft Auto VI24.6.2026 12:15:00 CEST | Press release
Starting at Midnight Local Time on June 25, 2026 Rockstar Games®, a publishing label of Take-Two Interactive Software, Inc. (NASDAQ: TTWO), is excited to announce that pre-orders for Grand Theft Auto VI will begin on June 25, 2026, at midnight local time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260624539426/en/ Rockstar Games®, a publishing label of Take-Two Interactive Software, Inc. (NASDAQ: TTWO), is excited to announce that pre-orders for Grand Theft Auto VI will begin on June 25, 2026, at midnight local time. Launching November 19, 2026, for the PlayStation® 5 computer entertainment systems and Xbox Series X|S games and entertainment systems for $79.99, Grand Theft Auto VI features a single-player experience set in the biggest, most immersive evolution of the series yet. Launching November 19, 2026, for the PlayStation® 5 computer entertainment systems and Xbox Series X|S games and entertainment systems for $79.9
Advanced Sterilization Products (ASP) Acquires a Majority Stake in UV Smart24.6.2026 12:00:00 CEST | Press release
Advanced Sterilization Products (ASP), part of the Infection Prevention group of companies within Fortive (NYSE: FTV), announced today it has acquired a majority share of UV Smart, a leader in High Level Disinfection technology in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260624367451/en/ UV Smart is renowned for its UV-C High Level Disinfection (HLD) technology that enables faster, safer and lower-cost HLD for specialty scopes. “UV Smart’s dedicated customer relationships and highly skilled team are key strengths that align perfectly with ASP’s long-term growth strategy of infection prevention,” shared Daan Hoek, co-founder of UV Smart. He continued, “Where current cleaning & disinfection processes of TEE probes can often take hours, UV Smart’s premier product, the D60, achieves high-level disinfection using UV-C light in just minutes. For healthcare providers, the D60 represents a significant improvement in ef
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom